Strategic partnerships WB’s collaboration history with RoosterBio and other biotechs shows a track record in forming strategic CDMO partnerships to advance clinical programs, indicating a receptive environment for co-developed manufacturing solutions and long-term engagements.

Clinical scale</tagline> With over 320 clinical grade products manufactured and experience across plasmid DNA, MSCs, hESCs, adenoviral and lentiviral vectors, WB positions itself as a versatile partner capable of supporting multiple modalities through IND enabling campaigns.

Industrious capabilities WB offers cGMP at a dedicated facility and provides full CMC support, batch records QA auditing, and access to a Type V Facility Master File, enabling clients to streamline IND submissions and accelerate regulatory readiness.

Clinical vaccine work Past and ongoing collaborations in vaccine development and COVID-19 programs illustrate WB’s capacity to handle vaccine-grade production and fast-paced timelines, presenting an opportunity to engage biotech firms pursuing phase I/II trials.

Growth potential Mid-sized CDMO with revenue in the 10–25 million range and a focus on cost-effective, timely manufacturing suggests opportunities to upsell advanced analytics, process development, and fill-finish services to emerging biotechs expanding their clinical portfolios.